UNSPSC 51291704: Desvenlafaxine

This classification denotes an antidepressant agent with the molecular formula C16H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NG99554ANW, chemically known as phenol, 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)- but generally known as desvenlafaxine, which bears US NIH Compound Identifier 125017. European Medicines Agency schedules Desvenlafaxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25380.

UNSPSC 51291704 Desvenlafaxine is a Commodity code that nominally designates a specific antidepressant pharmaceutical, but recent state and local solicitation activity under this code bears little direct relevance to the drug itself. The three most recent opportunities tagged to the code involve procurement of naloxone and drug deactivation systems (Seminole County, Florida), a market-intelligence RFI on direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and a cooperative-purchasing RFP for generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mismatch between the code's nominal scope and the actual work being bought suggests that state and local procurement offices are applying this code as a catch-all for pharmaceutical and related health-product procurement rather than as a precise commodity classifier. Issuing bodies include county health agencies, state health departments, and regional cooperative purchasing consortia; MMCAP, administered by the Minnesota Department of Administration, appears as a repeat buyer serving multiple state and local jurisdictions.

Recent activity spans Florida, Texas, and Minnesota, with the most concrete solicitation being Seminole County's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023 (note the retroactive deadline date in the source), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas HHS Commission issued an RFI (HHS0017013) on March 27, 2026 with an April 3, 2026 response deadline to gather vendor capabilities on direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP's RFP (S1070000015802), posted January 20, 2026 with a March 26, 2026 response deadline, seeks multiple manufacturers to supply generic pharmaceuticals and OTC products through three authorized wholesalers, with contract awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. The code shows fragmented activity across different commodity families (controlled substances, OTC products, cooperative agreements) rather than focused purchasing of a single pharmaceutical product.